NOVEL PUMP FOR TIDAL FLOW EXTRACORPOREAL SUPPORT

体外循环用于多种血液治疗应用，包括血液透析、呼吸支持（例如ECMO）和血液加温/冷却。这些应用中的大多数依赖于两个血管通路部位，一个用于引流血液，另一个用于返回经处理的血液。最近引入的血泵技术使得在患者和体外血液处理系统之间交换血液的单套管潮汐流系统的使用成为可能。单套管系统的使用相对于当前的双套管系统具有相当大的成本和安全性优势。将开发一种潮汐流体外血泵（T-Pump），该泵由一个带有整体流量切换机构的血泵和控制软件组成。泵的设计和测试将考虑其产生足够血流的能力，以向成人提供全面呼吸支持，并为血液透析提供适当的血流和压力条件。将进行台架测试，以表征用于这些体外血液处理应用的T型泵系统。拟议的商业应用：本文提出的技术将有可能应用于所有有体外血液治疗适应症的患者，并将降低发病率和护理成本。血液透析市场是该技术迄今为止最大的潜在应用，并且在呼吸支持领域存在显著的可能性（例如，ECMO）。体外肝透析和热循环作为癌症和艾滋病治疗的辅助治疗也将是拟议系统的潜在商业应用。

Extracorporeal circulation is used in several blood treatment applications including hemodialysis, respiratory support (e.g. ECMO), and blood warming/cooling. The majority of these applications rely on two vascular access sites, one for draining blood and the other for returning treated blood. Recently introduced blood pump technology makes possible the use of a single cannula tidal flow system of exchanging blood between a patient and an extracorporeal blood treatment system. The use of a single cannula system has considerable cost and safety advantages over the current two-cannula system. A tidal flow extracorporeal blood pump (T-Pump) will be developed, composed of a blood pump with an integral flow switching mechanism and controlling software. The pump will be designed and tested with regard to its ability to produce sufficient blood flow to provide total respiratory support to an adult and to provide appropriate blood flow and pressure conditions for hemodialysis. Bench testing will be conducted to characterize the T-Pump system for use in these extracorporeal blood treatment applications. PROPOSED COMMERCIAL APPLICATIONS: The technology proposed here will have potential application to all patients with indications for extracorporeal blood treatment and will offer reduced morbidity and cost of care. The hemodialysis market is by far the largest potential application of this technology, and significant possibilities exist in the area of respiratory support (e.g., ECMO). Extracorporeal liver dialysis and hyperthermic circulation as adjuvant therapy in cancer and HIV treatment would also be potential commercial applications for the proposed system.